PMCB (PharmaCyte Biotech) Market Cap: $8.15 Mil (As of Jun. 25, 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Market Cap?

PharmaCyte Biotech PMCB -0.30% 32 Market Cap is $8.15 Mil as of Jun. 25, 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 1,431 Biotechnology companies, PharmaCyte Biotech ranks worse than 86.51% on this metric.

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). PharmaCyte Biotech's share price for the quarter that ended in Jan. 2026 was $0.819. PharmaCyte Biotech's Shares Outstanding (EOP) for the quarter that ended in Jan. 2026 was 10.74 Mil. Therefore, PharmaCyte Biotech's market cap for the quarter that ended in Jan. 2026 was $8.79 Mil.

PharmaCyte Biotech's quarterly market cap declined from Jul. 2025 ($6.93 Mil) to Oct. 2025 ($6.32 Mil) but then increased from Oct. 2025 ($6.32 Mil) to Jan. 2026 ($8.79 Mil).

PharmaCyte Biotech's annual market cap declined from Apr. 2023 ($49.04 Mil) to Apr. 2024 ($17.04 Mil) and declined from Apr. 2024 ($17.04 Mil) to Apr. 2025 ($8.43 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. PharmaCyte Biotech's Enterprise Value for Today is $-11.52 Mil.


PharmaCyte Biotech  (NAS:PMCB) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


PharmaCyte Biotech Market Cap Related Terms


PharmaCyte Biotech Market Cap Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Market Cap Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Market Cap
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.24 48.28 49.04 17.04 8.43

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.08 8.43 6.93 6.32 8.79

PMCB vs IMNN, ACXP, ENVB: Market Cap Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech Market Cap vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Market Cap distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Market Cap falls into.


PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Market Cap is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

PharmaCyte Biotech's Market Cap for the fiscal year that ended in Apr. 2025 is calculated as

Market Cap (A: Apr. 2025 )=Share Price (A: Apr. 2025 )*Shares Outstanding (EOP) (A: Apr. 2025 )
=$1.24*6.796
=$8.43

PharmaCyte Biotech's Market Cap for the quarter that ended in Jan. 2026 is calculated as

Market Cap (Q: Jan. 2026 )=Share Price (Q: Jan. 2026 )*Shares Outstanding (EOP) (Q: Jan. 2026 )
=$0.819*10.736
=$8.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Market Cap →
What does a Market Cap of $8.15 Mil mean?
PharmaCyte Biotech (PMCB) has a Market Cap of $8.15 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #1238 out of 1431 companies in the Biotechnology industry, placing it in the top 86.5%.
Is PharmaCyte Biotech's Market Cap too high?
PharmaCyte Biotech's current Market Cap is $8.15 Mil. The Biotechnology industry median Market Cap is 117.63. PharmaCyte Biotech's value of $8.15 Mil is 93.1% below this industry median. Based on the distribution chart, PharmaCyte Biotech ranks #1238 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Market Cap compare to IMNN and ACXP?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #1238 out of 1431 companies for Market Cap. This places PharmaCyte Biotech in the lower half of its industry. The industry median Market Cap is 117.63. PharmaCyte Biotech's value of $8.15 Mil is 93.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCyte Biotech's current Market Cap of $8.15 Mil is 93.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on PharmaCyte Biotech and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCyte Biotech's current Market Cap is $8.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Market Cap of $8.15 Mil. The current Market Cap is $8.15 Mil and 93.1% below the Biotechnology industry median of 117.63. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Market Cap is $8.15 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price